Kinepict Ltd.

Medical X-ray causes >25.000 new cancer cases annually, while iodinated contrast media is the leading cause of hospital-acquired acute kidney injury and associated mortality.
Kinepict is developing novel method to reduce X-ray exposure and contrast media without sacrificing image quality.

Carbon dioxide X-ray angiography use is limited by poor image quality which can be improved with our technology. We use our technology’s better image quality to reduce X-ray and/or iodinated contrast material dose in X-ray angiography.

The clinical evaluation showed 2.3x better signal/noise ratio compared to DSA (42 patients, 200+ images). Validation of X-ray dose and contrast media reduction ongoing.


Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *